Ricky Goldwasser
Stock Analyst at Morgan Stanley
(4.23)
# 432
Out of 5,182 analysts
233
Total ratings
64.46%
Success rate
9.68%
Average return
Main Sectors:
Stocks Rated by Ricky Goldwasser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNC Centene | Maintains: Equal-Weight | $38 → $45 | $43.50 | +3.45% | 15 | Mar 4, 2026 | |
| DOCS Doximity | Maintains: Overweight | $65 → $49 | $24.66 | +98.70% | 12 | Feb 6, 2026 | |
| UNH UnitedHealth Group | Maintains: Overweight | $411 → $409 | $354.69 | +15.31% | 21 | Jan 23, 2026 | |
| CRL Charles River Laboratories International | Maintains: Equal-Weight | $170 → $185 | $171.23 | +8.04% | 23 | Nov 11, 2025 | |
| LH Labcorp Holdings | Maintains: Overweight | $283 → $306 | $263.43 | +16.16% | 17 | Jul 25, 2025 | |
| LFST LifeStance Health Group | Reiterates: Overweight | $10 | $7.27 | +37.55% | 8 | Apr 22, 2024 | |
| GDRX GoodRx Holdings | Maintains: Equal-Weight | $8 → $5.5 | $2.28 | +141.23% | 9 | Nov 10, 2023 | |
| OSCR Oscar Health | Maintains: Equal-Weight | $5 → $7.5 | $17.18 | -56.34% | 6 | Aug 30, 2023 | |
| ALHC Alignment Healthcare | Maintains: Overweight | $19 → $12 | $20.95 | -42.72% | 8 | Aug 30, 2023 | |
| DGX Quest Diagnostics | Reiterates: Equal-Weight | $145 | $196.63 | -26.26% | 17 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $365 | $179.22 | +103.66% | 7 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $403 → $420 | $828.32 | -49.29% | 27 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $120 | $6.14 | +1,854.40% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $549 → $620 | $223.62 | +177.26% | 11 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $485 → $500 | $356.13 | +40.40% | 2 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $124 | $78.36 | +58.24% | 9 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $296 → $318 | $282.58 | +12.53% | 11 | Aug 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $70 | $202.34 | -65.40% | 17 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $182 → $195 | $163.84 | +19.02% | 6 | Oct 21, 2020 |
Centene
Mar 4, 2026
Maintains: Equal-Weight
Price Target: $38 → $45
Current: $43.50
Upside: +3.45%
Doximity
Feb 6, 2026
Maintains: Overweight
Price Target: $65 → $49
Current: $24.66
Upside: +98.70%
UnitedHealth Group
Jan 23, 2026
Maintains: Overweight
Price Target: $411 → $409
Current: $354.69
Upside: +15.31%
Charles River Laboratories International
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $170 → $185
Current: $171.23
Upside: +8.04%
Labcorp Holdings
Jul 25, 2025
Maintains: Overweight
Price Target: $283 → $306
Current: $263.43
Upside: +16.16%
LifeStance Health Group
Apr 22, 2024
Reiterates: Overweight
Price Target: $10
Current: $7.27
Upside: +37.55%
GoodRx Holdings
Nov 10, 2023
Maintains: Equal-Weight
Price Target: $8 → $5.5
Current: $2.28
Upside: +141.23%
Oscar Health
Aug 30, 2023
Maintains: Equal-Weight
Price Target: $5 → $7.5
Current: $17.18
Upside: -56.34%
Alignment Healthcare
Aug 30, 2023
Maintains: Overweight
Price Target: $19 → $12
Current: $20.95
Upside: -42.72%
Quest Diagnostics
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $145
Current: $196.63
Upside: -26.26%
Jul 14, 2023
Reiterates: Overweight
Price Target: $365
Current: $179.22
Upside: +103.66%
Jan 6, 2023
Maintains: Overweight
Price Target: $403 → $420
Current: $828.32
Upside: -49.29%
Jan 6, 2023
Maintains: Overweight
Price Target: $140 → $120
Current: $6.14
Upside: +1,854.40%
Oct 31, 2022
Maintains: Overweight
Price Target: $549 → $620
Current: $223.62
Upside: +177.26%
Oct 21, 2022
Maintains: Equal-Weight
Price Target: $485 → $500
Current: $356.13
Upside: +40.40%
Oct 11, 2022
Maintains: Overweight
Price Target: $127 → $124
Current: $78.36
Upside: +58.24%
Aug 17, 2022
Maintains: Overweight
Price Target: $296 → $318
Current: $282.58
Upside: +12.53%
Jul 14, 2022
Maintains: Overweight
Price Target: $74 → $70
Current: $202.34
Upside: -65.40%
Oct 21, 2020
Maintains: Overweight
Price Target: $182 → $195
Current: $163.84
Upside: +19.02%